Gelonghui, January 9 | Guizhou Sanli (603439.SH) announced its 2023 annual results forecast. The company expects to achieve net profit attributable to shareholders of listed companies of 28700,000 yuan to 30.75 million yuan in 2023, an increase of 42.58% to 52.77% compared with the same period last year. The company expects net profit attributable to the owner of the parent company in 2023 after deducting non-recurring profit and loss of RMB 233.90 million to RMB 25.440 million, an increase of 20.17% to 30.71% over the previous year.
In the first quarter and fourth quarter of 2023, there was a sharp increase in the number of cases of throat diseases and influenza in China, and demand for related drugs increased dramatically. The market demand for the company's core products, Throat Sword Spray and Throat Sword Spray (children's type), was strong, and the company's sales increased. In the third quarter of 2023, the construction of the company's OTC channel began to gradually increase, so that the company's revenue maintained steady growth.